Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Although celecoxib may provide perioperative pain relief, the effect of the short-term use of celecoxib on bone ingrowth into porous-coated devices has not been previously studied in humans. Bone ingrowth into titanium and tantalum plugs was measured in nine patients who underwent staged bilateral total knee arthroplasty (TKA) and were taking celecoxib as part of a perioperative pain relief protocol. Patients were given tetracycline to measure the mineral apposition rate before and after celecoxib administration. Time zero plugs were implanted and retrieved during the first TKA, and 12 weeks later the contralateral implanted plugs were retrieved at the second TKA. The mineral apposition rate was similar for the titanium (0.97 microm per day) and the tantalum (1.15 microm per day) plugs at 12 weeks as was bone ingrowth (886 microm versus 632 microm, respectively). Celecoxib does not seem to inhibit bone ingrowth or bone formation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.blo.0000238838.18799.61 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!